Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam Completes Enrollment in Phase II Study of ATTR Drug

Premium

Alnylam Pharmaceuticals this week announced that it has completed enrollment in a phase II trial of its lipid nanoparticle-formulated TTR-mediated amyloidosis treatment ALN-TTR02.

The phase II open-label trial is evaluating two doses of ALN-TTR02, ranging from 0.01 mg/kg to 0.30 mg/kg, in 29 patients with ATTR polyneuropathy. Patients are treated either once every four weeks or once every three weeks.

This summer, the company reported positive interim data from the trial showing that its drug was able to knock down levels of the protein that causes the disease by as much as 93 percent (GSN 7/3/2013).

Alnylam said that it remains on track to begin a phase III trial of ALN-TTR02 in ATTR patients with a manifestation of the condition called familial amyloidotic polyneuropathy by the end of this year.

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.